Safety and Efficacy of Emicizumab in Persons With Haemophilia A With / Without FVIII Inhibitors: Pooled Data from Four Phase III Studies (HAVEN 1–4)

Michael U. Callaghan,1 Claude Négrier,2 Ido Paz-Priel,3 Tiffany Chang,3† Sammy Chebon,4 Michaela Lehle,4 Johnny Mahlangu,5 Guy Young,6 Rebecca Kruse-Jarres,7 Maria Elisa Mancuso,8† Markus Niggli,4 Monet Howard,9 Nives Selak Bienz,4 Midori Shima,10 Victor Jiménez-Yuste,11 Christophe Schmitt,4 Elina Asikanis,4† Gallia Levy,3† Steven Pipe,12 and Johannes Oldenburg13

1Children’s Hospital of Michigan, Detroit, MI, USA; 2 Edouard Herriot University Hospital, Lyon, France; 3Genentech, Inc., South San Francisco, CA, USA; 4F. Hoffmann-La Roche Ltd, Basel, Switzerland; 5University of the Witwatersrand and NHLS, Johannesburg, South Africa; 6Children’s Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA, USA; 7Bloodworks Northwest, Seattle, WA, USA; 8Angelo Bianchi Bonomi Haemophilia and Thrombosis Center, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milano, Italy; 9F. Hoffmann-La Roche Ltd, Mississauga, Canada; 10Nara Medical University Hospital, Kashihara, Japan; 11Hospital Universitario La Paz, Autonoma University, Madrid, Spain; 12University of Michigan, Ann Arbor, MI, USA; 13University of Bonn, Bonn, Germany.

New affiliations:
*Spark Therapeutics, Inc., Philadelphia, PA, USA; †Center for Thrombosis and Hemorrhagic Diseases, Humanitas Clinical and Research Center - IRCCS, Rozzano, Milan, Italy; ‡Finnish Health Authority, Helsinki, Finland.

Key takeaways

• With nearly 3 years of follow-up, emicizumab maintained low bleed rates in persons with haemophilia A of all ages, with and without FVIII inhibitors; almost all target joints resolved
• Emicizumab remains well tolerated over long-term follow-up, and no new safety concerns were identified in this analysis

Acknowledgements
The authors would like to thank the study participants and their families, study investigators, coordinators and site personnel. This study was sponsored by F. Hoffmann-La Roche Ltd and Genentech, Inc. Third party medical writing assistance, under the direction of the authors, was provided by Rebecca A. Bachmann, PhD, of Gardiner-Caldwell Communications and was funded by F. Hoffmann-La Roche Ltd and Genentech, Inc.

Disclosures*
MUC: Shareholder of: Alnylam; Grant/research support from: Pfizer; Consultant for: F. Hoffmann-La Roche Ltd, Genentech, Inc., Takeda, Sanofi, Pfizer, Bayer, Global Blood Therapeutics, Bluebird Bio, UniQure, Spark, BioMarin, Kedrion, Grifols, Hema Biologics; Speaker Bureau of: F. Hoffmann-La Roche Ltd and Genentech, Inc.

*See manuscript (Callaghan MU, et al. Blood 2020; published online) for all authors’ disclosures.
Pooled data from HAVEN 1–4 Phase III studies demonstrated durable efficacy of emicizumab in PwHA (data cut-off 15 May, 2020) following 970.3 patient-years of exposure.

- Participants (N=401) had a median (range) age of 28.0 (1–77) years; in total, 400* participants were included in the efficacy-analysis population and 399* in the safety-analysis population.

HAVEN 1
NCT02622321
Adult/adolescent (≥12 years) PwHA with FVIII inhibitors (N=113)
Emicizumab 1.5 mg/kg QW

HAVEN 2
NCT02795767
Paediatric (<12 years) PwHA with FVIII inhibitors (N=88)
Emicizumab 1.5 mg/kg QW, 3.0 mg/kg Q2W or 6.0 mg/kg Q4W

HAVEN 3
NCT02847637
Adult/adolescent (≥12 years) PwHA without FVIII inhibitors (N=152)
Emicizumab 1.5 mg/kg QW, or 3.0 mg/kg Q2W

HAVEN 4
NCT03020160
Adult/adolescent (≥12 years) PwHA with or without FVIII inhibitors (N=48)
Emicizumab 6.0 mg/kg Q4W

At clinical cut-off, 95.1% (n=504/530) of target joints in 226 evaluable PwHA resolved† with emicizumab prophylaxis.

Among 226 evaluable PwHA who had at least one target joint at baseline and received at least 52 weeks of emicizumab prophylaxis, 89.4% (n=202/226) had zero target joint bleeds.

The percentage of PwHA with zero treated bleeds increased over the first year and remained >80% thereafter. After Week 24, at least 97% of PwHA had ≤3 bleeds in each 24-week treatment interval.

*One participant in HAVEN 3 assigned to ‘no prophylaxis’ was lost to follow-up prior to the switch to emicizumab and was, therefore, not treated and excluded from the efficacy and safety analysis. One participant in HAVEN 1 discontinued prior to emicizumab treatment and was excluded from the safety analyses.

†Determined using a negative-binomial regression model.

‡Target joint resolution: ≤2 spontaneous or traumatic bleeding events in an existing target joint within a continuous 52-week period.

ABR, annualised bleed rate; CI, confidence interval; FVIII, factor VIII; PwHA, persons with haemophilia A; QW, once weekly; Q2W, once every 2 weeks; Q4W, once every 4 weeks.

During 970 patient-years of exposure, emicizumab had a favourable long-term safety profile with no new or unexpected signals.

### All AEs

<table>
<thead>
<tr>
<th>Event</th>
<th>Total population (N=399)</th>
</tr>
</thead>
<tbody>
<tr>
<td>At least one AE, n (%)</td>
<td>381 (95.5)</td>
</tr>
<tr>
<td>Local injection-site reaction, n (%)</td>
<td>111 (27.8)</td>
</tr>
<tr>
<td>Treatment-related AE, n (%)</td>
<td>139 (34.8)*</td>
</tr>
<tr>
<td>Grade ≥3 AE†, n (%)</td>
<td>87 (21.8)</td>
</tr>
<tr>
<td>AE leading to withdrawal from treatment, n (%)</td>
<td>5 (1.3)</td>
</tr>
<tr>
<td>Serious AE, n (%)</td>
<td>93 (23.3)</td>
</tr>
<tr>
<td>AE with fatal outcome, n (%)</td>
<td>1 (0.3)††</td>
</tr>
</tbody>
</table>

### AEs of special interest

<table>
<thead>
<tr>
<th>Event</th>
<th>Total population (N=399)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Systemic hypersensitivity/anaphylactic reaction,§ n (%)</td>
<td>1 (0.3)</td>
</tr>
<tr>
<td>TE associated with concomitant aPCC use, n (%)</td>
<td>2 (0.5)</td>
</tr>
<tr>
<td>Other TE, n (%)</td>
<td>2 (0.5)</td>
</tr>
<tr>
<td>Device occlusion of a peripherally inserted central catheter</td>
<td>1 (0.3)†</td>
</tr>
<tr>
<td>Myocardial infarction</td>
<td>1 (0.3)†</td>
</tr>
<tr>
<td>TMA associated with concomitant aPCC use, n (%)</td>
<td>3 (0.8)€</td>
</tr>
<tr>
<td>Other TMA, n (%)</td>
<td>0 (0.0)</td>
</tr>
</tbody>
</table>

---

**No participants discontinued due to AEs beyond the 5 previously described in the primary analyses**

- The device occlusion and MI events**‡‡** were assessed by the Investigators as unrelated to emicizumab. Both events resolved, and each individual continued emicizumab.

---

*One participant in HAVEN 4 was missing data on AE relationship to treatment. †Adverse events were graded according to the World Health Organization toxicity grading scale. ‡Death of one participant in HAVEN 1 was caused by rectal haemorrhage. §Assessed using Sampson criteria and includes all participants who experienced indicative symptoms. One participant was identified through algorithmic analysis as potentially having a systemic hypersensitivity/anaphylactic/anaphylactoid reaction (he had experienced symptoms of abdominal pain and cough); however, medical review of the case showed that Sampson criteria were not met. †The person with the non-serious device occlusion had a history of device-related thrombosis before receiving emicizumab. The person with MI was >65 years, had previously undiagnosed coronary artery disease, was treated for the event, and recovered with reduced heart function. ††No new cases of thrombotic microangiopathy have been reported since the primary study analyses. Data cut-off: 15 May, 2020. AE, adverse event; aPCC, activated prothrombin complex concentrate; MI, myocardial infarction; TE, thrombotic event; TMA, thrombotic microangiopathy.

Conclusions

With nearly 3 years of follow-up, emicizumab maintained low bleed rates in PwHA of all ages, with and without FVIII inhibitors.

ABRs decreased over time and the proportion of participants with zero treated bleeds increased; almost all target joints resolved.

Emicizumab remains well tolerated over long-term follow-up, and no new safety concerns were identified in this analysis.

Long-term safety and efficacy data for emicizumab are consistent with the findings of the primary analyses and indicate continued reductions in bleeding with long-term treatment.

Please see full publication (Callaghan MU, et al. *Blood* 2020; doi: [10.1182/blood.2020009217](https://doi.org/10.1182/blood.2020009217)) for further details.

ABR, annualised bleed rate; FVIII, factor VIII; PwHA, persons with haemophilia A.